DAX23.881 +0,6%ESt505.530 +0,4%Top 10 Crypto15,85 -0,4%Dow46.398 +0,2%Nas22.660 +0,3%Bitcoin97.171 -0,3%Euro1,1736 ±-0,0%Öl67,06 -0,9%Gold3.859 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 Lufthansa 823212 RENK RENK73 Wolfspeed A41JEH NVIDIA 918422 HENSOLDT HAG000 Alibaba A117ME Novo Nordisk A3EU6F Tesla A1CX3T Siemens Energy ENER6Y BYD A0M4W9 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown droht: US-Börsen schließen dennoch höher -- DAX letztlich fester -- CoreWeave, Meta, Lufthansa, Continental, Alibaba, Tilray, Clara Technologies, Wolfspeed, Firefly, Etsy, Shopify im Fokus
Top News
3. Quartal 2025: So bewegten sich die DAX-Aktien im vergangenen Quartal 3. Quartal 2025: So bewegten sich die DAX-Aktien im vergangenen Quartal
Tesla-Aktie vor erneutem Schub: Überraschen die Auslieferungszahlen positiv? Tesla-Aktie vor erneutem Schub: Überraschen die Auslieferungszahlen positiv?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Biomarin Pharmaceutical Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
45,86 EUR -0,07 EUR -0,15 %
BMN
54,16 USD +0,14 USD +0,25 %
BTT
Biomarin Pharmaceutical jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.8,81 Mrd. EUR

KGV29,78Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN924801

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS09061G1013

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBMRN

Biomarin Pharmaceutical Aktien News

DatumMeistgelesen
ZacksWhy BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
PR NewswireBioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia ...
PR NewswireBioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
PR NewswireBioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
PR NewswireBioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
PR NewswireBioMarin Announces New R&D and Business Development Leadership
PR NewswireBioMarin to Host 2024 Investor Day on September 4th in New York
PR NewswireBioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
PR NewswireBioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
PR NewswireU.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
PR NewswireBioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET
PR NewswireBioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's...
PR NewswireKKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PR NewswireBioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024...
PR NewswireBioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
PR NewswireBioMarin Reports Record Financial Results for the First Quarter 2024
PR NewswireBioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
PR NewswireNew Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical ...
PR NewswireBioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
PR NewswireBioMarin Scheduled to Participate in March Investor Conferences
PR NewswireBioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
PR NewswireBioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
PR NewswireBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
PR NewswireBioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
PR NewswireBioMarin Announces Governance Enhancements and Value Creation Initiatives
PR NewswireBioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
PR NewswireBioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
PR NewswireBioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
PR NewswireU.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
PR NewswireBioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
PR NewswireBioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
PR NewswireBioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
PR NewswireBioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
PR NewswireBioMarin to Participate in Three Upcoming Investor Conferences
PR NewswireBioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
PR NewswireBioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
PR NewswireBioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET
PR NewswireU.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
PR NewswireBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis ...
PR NewswireBioMarin to Participate in Bank of America 2023 Health Care Conference

Biomarin Pharmaceutical News

Biomarin Pharmaceutical News: auf dieser Seite finden Sie alle Biomarin Pharmaceutical News und Nachrichten zur Biomarin Pharmaceutical Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biomarin Pharmaceutical News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biomarin Pharmaceutical News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.